Clinical Research
Future in doubt as Opthea’s AMD drug flunks first pivotal study
Opthea ‘s, Opthea, Future, Clinical Research
Supernus Pharmaceuticals’ Depression Drug SPN-820 Fails to Meet Primary Endpoint in Phase 2b Trial
Supernus Pharmaceuticals, SPN-820, treatment-resistant depression, Phase 2b trial, clinical study failure, MADRS score, placebo effect
Stoke Therapeutics Announces Global Phase 3 EMPEROR Study Design for Zorevunersen in Dravet Syndrome
Dravet syndrome, zorevunersen, Phase 3 trial, EMPEROR study, seizure reduction, cognitive improvement, regulatory alignment
Roche’s Itovebi Demonstrates Significant Overall Survival Benefit in Advanced Breast Cancer Study
Itovebi, inavolisib, breast cancer, PIK3CA mutation, overall survival, INAVO120 study, Roche
Neumora’s Navacaprant Fails to Meet Expectations in First Phase 3 Trial for Major Depressive Disorder
Neumora Therapeutics, Navacaprant, Major Depressive Disorder, Phase 3 Trial, KOASTAL-1 Study
Javara Undergoes Restructuring, Lays Off Staff Amidst Industry-Wide Challenges
Javara, layoffs, restructuring, clinical research, biopharma industry challenges
SIGA’s TPOXX Fails to Demonstrate Efficacy in Treating Mild to Moderate Mpox Cases: STOMP Study Results
SIGA Technologies, TPOXX, Tecovirimat, Mpox, STOMP Study, Antiviral Treatment, Efficacy, Safety Profile
Empowering Patients: The Key to Faster, More Impactful Research
Patient-centered care, Patient engagement, Personalized medicine, Clinical research, Healthcare outcomes, Patient empowerment
Sanofi’s Rilzabrutinib Shows Promising Results in Phase III Trial for Immune Thrombocytopenia (ITP)
Rilzabrutinib, BTK inhibitor, Immune Thrombocytopenia (ITP), Phase III trial, Sanofi, LUNA 3 study
Jasper Therapeutics Escalates Dose in Hives Trial Following Rapid Complete Responses
Jasper Therapeutics, briquilimab, chronic inducible urticaria, hives, dose escalation, clinical trial, SPOTLIGHT study